Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, discusses challenges associated with developing cell therapies for clinical use. Chemistry, Manufacturing and Controls (CMC) remains a major barrier for many manufacturers, which lead to the creation of genetically engineered induced pluripotent stem cell-(iPSC)-derived mesenchymal stem cells (MSCs). Dr Ting additionally highlights how genetically engineered therapies can overcome regulatory issues relating to potency assays. This interview took place at Advanced Therapies Week 2022.
Tony Ting, PhD, is an employee of Bone Therapeutics.